Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2024

Open Access 01-12-2024 | Inotuzumab Ozogamicin | Review

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Authors: Nicholas J. Short, Elias Jabbour, Nitin Jain, Hagop Kantarjian

Published in: Journal of Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Literature
1.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375:740–53.PubMedPubMedCentralCrossRef
2.
DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–14.PubMedCrossRef
3.
DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res. 2004;10:8620–9.PubMedCrossRef
4.
DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against Non-hodgkin’s B-cell lymphoma. Clin Cancer Res. 2006;12:242–9.PubMedCrossRef
5.
de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255–64.PubMedCrossRef
6.
Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21:2240–5.PubMedCrossRef
7.
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–93.PubMedCrossRef
8.
Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Br J Haematol. 2018;182:583–6.PubMedCrossRef
9.
Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-hodgkin lymphoma (B-NHL). J Clin Oncol. 2014;32:8529.CrossRef
10.
Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–11.PubMedCrossRef
11.
Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–36.PubMedCrossRef
12.
DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167–80.PubMedPubMedCentralCrossRef
13.
DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10:81.PubMedPubMedCentralCrossRef
14.
Stock W, Martinelli G, Stelljes M, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127:905–13.PubMedCrossRef
15.
Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021;27:2742–54.PubMedCrossRef
16.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474–87.PubMedCrossRef
17.
Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after Inotuzumab Ozogamicin treatment for relapsed or refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transpl. 2019;25:1720–9.CrossRef
18.
Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4:e387–98.PubMedCrossRef
19.
Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2015;50:781–9.CrossRef
20.
Kebriaei PSR, Wallis W, et al. P739: predictive factors for developing veno-occlusive disease in patients with acute lymphoblastic leukemia treated with inotuzumab ozogamicin followed by allogeneic hematopoietic stem cell transplantation. Haematologica. 2017;102:299.
21.
Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transpl. 2018;53:449–56.CrossRef
22.
Giglio F, Xue E, Greco R, et al. Defibrotide Prophylaxis of Sinusoidal obstruction syndrome in adults treated with Inotuzumab Ozogamicin prior to hematopoietic stem cell transplantation. Front Oncol. 2022;12:933317.PubMedPubMedCentralCrossRef
23.
Jabbour E, Ravandi F, Kebriaei P, et al. Salvage Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative Acute Lymphoblastic Leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230–4.PubMedCrossRef
24.
Jabbour E, Sasaki K, Short NJ, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021;127:2025–38.PubMedCrossRef
25.
Kantarjian H, Haddad FG, Jain N, et al. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023;16:44.PubMedPubMedCentralCrossRef
26.
Haddad F, Jabbour E, Nasnas C et al. S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL. Hemasphere 2023;7.
27.
Short NJ, Jabbour E, Jamison T et al. Dose-dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab achieves Rapid MRD-Negativity in Philadelphia chromosome-negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia.
28.
Short NJ, Kantarjian H, Ravandi F, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022;6:4006–14.PubMedPubMedCentralCrossRef
29.
Kotrová M, Koopmann J, Trautmann H, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022;6:3006–10.PubMedPubMedCentralCrossRef
30.
Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463–71.PubMedPubMedCentralCrossRef
31.
O’Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113:2097–101.PubMedCrossRef
32.
Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19:240–8.PubMedCrossRef
33.
Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433–44.PubMedCrossRef
34.
Jabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125:2579–86.PubMedCrossRef
35.
Wieduwilt MJ, Yin J, Kour O, et al. Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. J Clin Oncol. 2023;41:7006.CrossRef
36.
Stelljes M, Raffel S, Alakel N et al. Inotuzumab Ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-Precursor ALL. J Clin Oncol 2023:Jco2300546.
37.
Chevallier P, Leguay T, KIM R, et al. Fractionated Inotuzumab Ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22 + Philadelphia chromosome (Ph)-Negative B-Cell precursor (BCP) Acute Lymphoblastic Leukemia (ALL): results of the EWALL-INO Study. Blood. 2022;140:6114–6.CrossRef
38.
Muffly L. ALLIANCE A042001: a Randomized Clinical Trial to determine whether inotuzumab + Mini-HyperCVD will replace HyperCVAD as Frontline Treatment in older adult ALL. The Hematologist 2023;20.
39.
Jabbour E, Short NJ, Jain N, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9:e878–85.PubMedCrossRef
40.
Nguyen D, Kantarjian HM, Short NJ, et al. Updated results from a phase II study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-Cell Acute Lymphoblastic Leukemia. Blood. 2023;142:4245.CrossRef
41.
Jabbour E, Gökbuget N, Advani A, et al. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020;88:106283.PubMedCrossRef
42.
Jabbour EJ, Haddad FG, Short NJ et al. Phase II study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024;143(5):417–21.
43.
Marconi G, Piciocchi A, Chiaretti S, et al. Gimema ALL2418: interim analysis of a phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult patients with B-Cell Acute Lymphoblastic Leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation. Blood. 2022;140:6119–21.CrossRef
44.
Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96:1000–7.PubMedPubMedCentralCrossRef
45.
Metheny L, Sobecks RM, Cho C et al. A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv 2024.
46.
Rubinstein JD, Breese EH, Krupski MC et al. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy. 2023;29:311.e1-.e7.
47.
Ceolin V, Brivio E, van Tinteren H, et al. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2023;37:53–60.PubMedCrossRef
48.
Shah BD, Cassaday RD, Park JH, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023;11:e007118.PubMedPubMedCentralCrossRef
49.
Jabbour E, Short NJ, Jain N, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16:22.PubMedPubMedCentralCrossRef
50.
Wintering A, Ishiyama K, Tamaki S, et al. CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2023;7:251–5.PubMedCrossRef
51.
Ryland GL, Barraclough A, Fong CY, et al. Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. Br J Haematol. 2020;191:123–6.PubMedCrossRef
52.
Zhao Y, Short NJ, Kantarjian HM et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024. (In press)
53.
Luskin MR, Shimony S, Keating J, et al. A phase I study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in adults. Blood. 2023;142:1509.CrossRef
Metadata
Title
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions
Authors
Nicholas J. Short
Elias Jabbour
Nitin Jain
Hagop Kantarjian
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-024-01552-7

Other articles of this Issue 1/2024

Journal of Hematology & Oncology 1/2024 Go to the issue

Correspondence

Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study

Research

Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

Correspondence

Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment

Correspondence

Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model

Review

Metabolic reprogramming in the tumor microenvironment of liver cancer

Correspondence

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits